Markian Bochan, MD
Infectious Disease · Carmel, INNPI 1972541936
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $37,406 of the $54,382 with a category attached, or 68.8%. 15 manufacturers reported payments, led by Tetraphase Pharmaceuticals, Inc. at 35.1% of the total. Reporting peaked in 2019 at $32,535 and has fallen 99.1% since, to $284 in 2025. Among infectious disease clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 103 payments — averaging $527.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tetraphase Pharmaceuticals, Inc.$19K
- Melinta Therapeutics, LLC$12K
- La Jolla Pharmaceutical Company$11K
- Ferring Pharmaceuticals Inc.$8K
- Amgen$2K
- AbbVie$619
- plus $1K from 9 others
Across 25 payments — averaging $829.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$21K
What the payments were for
- Consulting fees$7,68014%
- Speaking & faculty fees$37,40669%
- Grants$4501%
- Travel & lodging$5,0029%
- Food & beverage$3,8447%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tetraphase Pharmaceuticals, Inc. | 19 | $19,069 |
| Melinta Therapeutics, LLC | 17 | $12,468 |
| La Jolla Pharmaceutical Company | 18 | $11,416 |
| Ferring Pharmaceuticals Inc. | 3 | $7,680 |
| Amgen | 2 | $1,988 |
| AbbVie(2 entities) | 11 | $619 |
| Angiodynamics, Inc. | 4 | $355 |
| Merck | 11 | $275 |
| T2 Biosystems, Inc. | 2 | $238 |
| Johnson & Johnson | 5 | $87 |
| Insmed, Inc. | 4 | $76 |
| Viiv Healthcare Company | 3 | $52 |
| Gilead | 2 | $25 |
| Mayne Pharma Commercial LLC | 1 | $19 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$54,382 in reported general payments places this provider in the 95th percentile of 152 infectious disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 146 | $630,467 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 76 | $322,058 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 36 | $141,028 |
| AvycazCeftazidime/Avibactam | 11 | $114,924 |
| StribildElviteg/Cob/Emtri/Tenofo Disop | 11 | $53,394 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 12 | $50,390 |
| Daptomycin | 46 | $45,426 |
| JulucaDolutegravir/Rilpivirine | 11 | $38,015 |
| DescovyEmtricitabine/Tenofov Alafenam | 13 | $33,262 |
| DovatoDolutegravir Sodium/Lamivudine | 11 | $31,092 |
| Posaconazole | 13 | $27,931 |
| IsentressRaltegravir Potassium | 12 | $27,779 |
| ErtapenemErtapenem Sodium | 28 | $17,103 |
| Meropenem | 19 | $12,360 |
| CeftriaxoneCeftriaxone Sodium | 118 | $11,523 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Stribild, Descovy | $25 | $1,039,181246 claims |
| Viiv Healthcare CompanyTriumeq, Juluca, Dovato | $52 | $210,13558 claims |
| AbbVieAvycaz | $619 | $114,92411 claims |
| MerckIsentress | $275 | $27,77912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 152 infectious disease providers in Indiana.
Other infectious disease in Carmel
- Tracey IkerdCarmel$39K
- Francisco DelgadoCarmel$3K
- Joshua BergCarmel$1K
- Chad TewellCarmel$1K
- Hassan ElmalikCarmel$1K
- Joseph FraizCarmel$676
- Timothy FransonZionsville$303K
- Donald TherasseZionsville$75K
- Anwer JaffriTerre Haute$63K
- Jason BaileyFort Wayne$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.